Titlebook: New Findings on Aclarubicin in the Treatment of Acute Myeloid Leukemia; W. Hiddemann,R. Mertelsmann Conference proceedings 1990 Springer-V

impaction

978-3-540-52613-1Springer-Verlag Berlin Heidelberg 1990

文字

Aclarubicin in Single Agent and Combined Chemotherapy of Adult Acute Myeloid Leukemia,The present contribution summarizes the results of treating acute myeloid leukemia (AML) with aclarubicin (ACM) in three consecutive studies. Some of the results have recently been published elsewhere [1–3].

Engaged

mitral-valve

CAND

BYRE

mercenary

Low-Dose Aclacinomycin A in Myelodysplastic Syndromes and Subsequent Acute Myelogenous Leukemia: A median survival times as compared to those with no change (NC) or progressive disease (PD): 22 months for responders, 3 months for nonresponders. Censored median survival was 22 months for RAEB, 14 months for RAEB-T, but only 2 months for secondary ANLL. Evaluation of risk factors gave evidence of a

FER

滑稽

bination with conventional or intermediate- dose cytosine arabinoside or etoposide in patients with relapsed or refractory acute myeloid leukemia. The results reported indicate that aclacinomycin A has substantial activity in the treatment of hematologic malignancies. In summary, this book provides a valuable978-3-540-52613-1978-3-642-75720-4

cortisol

New Findings on Aclarubicin in the Treatment of Acute Myeloid Leukemia